The FDA Just Changed Something Important for Women Over 50, and Almost No One Is Talking About It

I spend a lot of time reading health search data for work, watching what people are actually typing into Google at 11pm when they think no one's paying attention. A few months ago, one search pattern kept showing up that I hadn't seen much of before: women looking for telemedicine options specifically for low libido.

That's not a new problem. What is new, and what most people writing about this still haven't caught up to, is that the FDA quietly closed a decade-long gap in December 2025.

Here's the background. In 2015, the FDA approved flibanserin, sold as Addyi, as the first medication specifically for hypoactive sexual desire disorder, or HSDD, in women. There was one significant catch. It was only approved for premenopausal women. If you were postmenopausal and dealing with the exact same distressing drop in desire, there was no FDA-approved medication option for you at all, for ten years, regardless of how similar your symptoms were to a premenopausal woman's.

In December 2025, the FDA approved an expanded indication for flibanserin covering postmenopausal women under 65. I pulled the actual approval letter rather than taking anyone's summary of it, and the language is direct: this closes a gap that sexual medicine specialists had been pushing on for a decade.

Why did this take so long, and why does it matter now. Postmenopausal HSDD is not rare. Some research places distressing low desire at anywhere from 12 to over 50 percent of women in the years around and after menopause, depending on how the studies define it. That's an enormous number of women who, until recently, had exactly one legitimate medication option available to them: off-label testosterone therapy, dosed and monitored according to guidance from a coalition of ten international medical societies, since no testosterone product is currently FDA-approved specifically for women in the US.

Now there's a second, FDA-approved, non-hormonal option on the table for that same population. That's a real shift, not a marketing one.

I went looking for a resource that actually explained this clearly, alongside the other common causes of low libido that get lumped in with "it's just menopause" when the real picture is usually more layered than that. This piece on women's libido telemedicine, covering both the causes and what a telehealth evaluation actually involves, is the most current breakdown I've come across, including a side-by-side of how the two FDA-approved medications actually differ.

If you're over 50 and have been told there was nothing to offer you beyond "that's just menopause," that assumption is now a decade out of date. Worth a second look.